Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody

PURPOSE: RG7116 is a novel anti-HER3 therapeutic antibody that inhibits HER3 signalling and induces antibody-dependent cellular cytotoxicity of tumor cells due to a glycoengineered antibody Fc moiety. We investigated the efficacy and pharmacokinetic/pharmacodynamic properties of HER3 signal inhibiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Meneses-Lorente, Georgina, Friess, Thomas, Kolm, Irene, Hölzlwimmer, Gabriele, Bader, Sabine, Meille, Christophe, Thomas, Marlene, Bossenmaier, Birgit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365277/
https://www.ncbi.nlm.nih.gov/pubmed/25702049
http://dx.doi.org/10.1007/s00280-015-2697-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365277/
https://www.ncbi.nlm.nih.gov/pubmed/25702049
http://dx.doi.org/10.1007/s00280-015-2697-8

Ejemplares similares